 - For the purposes of this study, poly ADP-ribose polymerase PARP inhibitors will be considered ?cytotoxic?; patients are allowed to receive, but are not required to receive, PARP inhibitors for management of primary or recurrentpersistent disease either alone or in combination with cytotoxic chemotherapy; PARP inhibitors will NOT count as a prior regimen when given alone 